Expected Versus Unexpected Delivery for Placenta Accreta Spectrum (PAS) Disorders with Same Team in Single Tertiary Center

Abstract

Objectives To evaluate the maternal and neonatal outcomes of expected and unexpected pathologically proven placenta accreta spectrum (PAS) cases in a single multidisciplinary center.

Material and Methods This was a retrospective cohort study of 92 PAS cases from January 2011 until September 2021. Only cases with histopathologically invasive placentation were included in the study. The cases diagnosed at the time of delivery were defined as unexpected PAS (uPAS) and those diagnosed antenatally as expected PAS (ePAS). Maternal and neonatal outcomes of both groups were compared.

Results Thirty-five (38%) of 92 cases were in the uPAS group. Placenta previa and high-grade PAS (percreata) were significantly higher in the ePAS group (p=0.028, p<0.001; respectively). The mean packed red blood cell transfusion was significantly higher in the uPAS group (p=0.030) but transfusions of other blood products were similar in the two groups. There was no significant difference in intraoperative complication rates between the two groups. Preterm delivery (<37 weeks) was significantly higher in the ePAS group (p<0.001), but there was no significant difference between the two groups in terms of adverse neonatal outcomes.

Conclusions Our single center data show that although ePAS cases include more highly invasive PAS cases, maternal hemorrhagic morbidity is lower than uPAS cases. Reducing maternal morbidity in PAS cases can be achieved by increasing antenatal diagnosis.

Key words

placenta accreta spectrum - placenta percreta - multidisciplinary management - prenatal diagnosis

Publication History

Received: 22 February 2022

Accepted after revision: 19 July 2022

Article published online:
13 September 2022

• References

• 1 Tantbirojn P, Crum CP, Parast MM.. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29: 639-645 DOI: 10.1016/j.placenta.2008.04.008.
• 2 Eller AG, Bennett MA, Sharshiner M. et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol 2011; 117: 331-337 DOI: 10.1097/AOG.0b013e3182051db2.
• 3 Miller DA, Chollet JA, Goodwin TM.. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177: 210-214 DOI: 10.1016/s0002-9378(97)70463-0.
• 4 Jauniaux E, Bunce C, Grønbeck L. et al. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol 2019; 221: 208-218 DOI: 10.1016/j.ajog.2019.01.233.
• 5 Karkhanis P, Ahmed I, Irani S.. Placenta accreta spectrum disorders – detection rate and maternal outcomes following implementation of an institutional protocol. J Obstet Gynaecol 2022; 42: 202-208 DOI: 10.1080/01443615.2021.1887110.
• 6 Wu S, Kocherginsky M, Hibbard JU.. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol 2005; 192: 1458-1461 DOI: 10.1016/j.ajog.2004.12.074.
• 7 Silver RM, Landon MB, Rouse DJ. et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107: 1226-1232 DOI: 10.1097/01.AOG.0000219750.79480.84.
• 8 Fitzpatrick KE, Sellers S, Spark P. et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG 2014; 121: 62-70 discussion 70–71 DOI: 10.1111/1471-0528.12405.
• 9 Shamshirsaz AA, Fox KA, Salmanian B. et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol 2015; 212: e1-9 DOI: 10.1016/j.ajog.2014.08.019.
• 10 Hasegawa J, Kurasaki A, Hata T. et al. Diagnosis of placenta accreta spectrum using ultra-high-frequency probe and superb microvascular imaging. Ultrasound Obstet Gynecol 2019; 54: 705-707 DOI: 10.1002/uog.20207.
• 11 Garofalo A, Pilloni E, Alemanno MG. et al. Ultrasound accuracy in prenatal diagnosis of abnormal placentation of posterior placenta previa. Eur J Obstet Gynecol Reprod Biol 2019; 242: 86-91 DOI: 10.1016/j.ejogrb.2019.09.021.
• 12 Silver RM, Fox KA, Barton JR. et al. Center of excellence for placenta accreta. Am J Obstet Gynecol 2015; 212: 561-568 DOI: 10.1016/j.ajog.2014.11.018.
• 13 Maison N, Rattanaburi A, Pruksanusak N. et al. Intraoperative blood volume loss according to gestational age at delivery among pregnant women with placenta accreta spectrum (PAS): an 11-year experience in Songklanagarind Hospital. J Obstet Gynaecol 2021; 1-6 DOI: 10.1080/01443615.2021.1910638.
• 14 Robinson BK, Grobman WA.. Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta. Obstet Gynecol 2010; 116: 835-842 DOI: 10.1097/AOG.0b013e3181f3588d.
• 15 Jauniaux E, Alfirevic Z, Bhide AG. et al. Placenta praevia and placenta accreta: diagnosis and management: Green-top guideline No. 27a. BJOG 2019; 126: e1-e48 DOI: 10.1111/1471-0528.15306.
• 16 Mitric C, Desilets J, Balayla J. et al. Surgical management of the placenta accreta spectrum: an institutional experience. J Obstet Gynaecol Can 2019; 41: 1551-1557 DOI: 10.1016/j.jogc.2019.01.016.
• 17 Allen L, Jauniaux E, Hobson S. et al. FIGO consensus guidelines on placenta accreta spectrum disorders: nonconservative surgical management. Int J Gynaecol Obstet 2018; 140: 281-290 DOI: 10.1002/ijgo.12409.
• 18 Sentilhes L, Kayem G, Chandraharan E. et al. FIGO consensus guidelines on placenta accreta spectrum disorders: conservative management. Int J Gynaecol Obstet 2018; 140: 291-298 DOI: 10.1002/ijgo.12410.
• 19 Fishel Bartal M, Papanna R, Zacharias NM. et al. Planned versus unplanned delivery for placenta accreta spectrum. Am J Perinatol 2022; 39: 252-258 DOI: 10.1055/s-0040-1714676.
• 20 Bailit JL, Grobman W, Rice MM. et al. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol 2015; 125: 683-689 DOI: 10.1097/AOG.0000000000000680.
• 21 Pettit KE, Stephenson ML, Truong YN. et al. Maternal and neonatal outcomes among scheduled versus unscheduled deliveries in women with prenatally diagnosed, pathologically proven placenta accreta. J Matern Fetal Neonatal Med 2019; 32: 927-931 DOI: 10.1080/14767058.2017.1395847.
• 22 Erfani H, Fox KA, Clark SL. et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol 2019; 221: e1-337.e5 DOI: 10.1016/j.ajog.2019.05.035.
• 23 Publications Committee, Society for Maternal-Fetal Medicine, Belfort MA. Placenta accreta. Am J Obstet Gynecol 2010; 203: 430-439 DOI: 10.1016/j.ajog.2010.09.013.
• 24 Fratto VM, Conturie CL, Ballas J. et al. Assessing the multidisciplinary team approaches to placenta accreta spectrum across five institutions within the University of California fetal Consortium (UCfC. J Matern Fetal Neonatal Med 2021; 34: 2971-2976 DOI: 10.1080/14767058.2019.1676411.
• 25 Eller AG, Porter TF, Soisson P. et al. Optimal management strategies for placenta accreta. BJOG 2009; 116: 648-654 DOI: 10.1111/j.1471-0528.2008.02037.x.
• 26 Warshak CR, Ramos GA, Eskander R. et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010; 115: 65-69 DOI: 10.1097/AOG.0b013e3181c4f12a.
• 27 Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol 2012; 120: 207-211 DOI: 10.1097/AOG.0b013e318262e340.
• 28 Bowman ZS, Eller AG, Kennedy AM. et al. Accuracy of ultrasound for the prediction of placenta accreta. Am J Obstet Gynecol 2014; 211: e1-7 DOI: 10.1016/j.ajog.2014.03.029.
• 29 Thurn L, Lindqvist PG, Jakobsson M. et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG 2016; 123: 1348-1355 DOI: 10.1111/1471-0528.13547.
• 30 Esakoff TF, Handler SJ, Granados JM. et al. PAMUS: placenta accreta management across the United States. J Matern Fetal Neonatal Med 2012; 25: 761-765 DOI: 10.3109/14767058.2011.598585.
• 31 Jolley JA, Nageotte MP, Wing DA. et al. Management of placenta accreta: a survey of maternal-fetal medicine practitioners. J Matern Fetal Neonatal Med 2012; 25: 756-760 DOI: 10.3109/14767058.2011.594467.
• 32 Wright JD, Silver RM, Bonanno C. et al. Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta. J Matern Fetal Neonatal Med 2013; 26: 1602-1609 DOI: 10.3109/14767058.2013.793662.
• 33 Sentilhes L, Ambroselli C, Kayem G. et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol 2010; 115: 526-534 DOI: 10.1097/AOG.0b013e3181d066d4.
• 34 Clausen C, Lönn L, Langhoff-Roos J.. Management of placenta percreta: a review of published cases. Acta Obstet Gynecol Scand 2014; 93: 138-143 DOI: 10.1111/aogs.12295.
• 35 O’Brien JM, Barton JR, Donaldson ES.. The management of placenta percreta: conservative and operative strategies. Am J Obstet Gynecol 1996; 175: 1632-1638 DOI: 10.1016/s0002-9378(96)70117-5.
• 36 Rac MWF, Wells CE, Twickler DM. et al. Placenta accreta and vaginal bleeding according to gestational age at delivery. Obstet Gynecol 2015; 125: 808-813 DOI: 10.1097/AOG.0000000000000674.
• 37 Perlman NC, Little SE, Thomas A. et al. Patient selection for later delivery timing with suspected previa-accreta. Acta Obstet Gynecol Scand 2017; 96: 1021-1028 DOI: 10.1111/aogs.13140.